Compare Glycorex Transplantation AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 106 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.20
0.00%
0.00
Revenue and Profits:
Net Sales:
9 Million
(Quarterly Results - Dec 2025)
Net Profit:
-3 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-1.64%
0%
-1.64%
6 Months
-29.15%
0%
-29.15%
1 Year
-27.78%
0%
-27.78%
2 Years
71.05%
0%
71.05%
3 Years
-62.06%
0%
-62.06%
4 Years
-77.14%
0%
-77.14%
5 Years
-82.82%
0%
-82.82%
Glycorex Transplantation AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
7.54%
EBIT Growth (5y)
3.80%
EBIT to Interest (avg)
-14.91
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.27
Sales to Capital Employed (avg)
4.58
Tax Ratio
0.67%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.87
EV to EBIT
-19.27
EV to EBITDA
74.01
EV to Capital Employed
4.74
EV to Sales
3.79
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-24.61%
ROE (Latest)
-20.29%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
No Trend
Mildly Bearish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
9.40
9.60
-2.08%
Operating Profit (PBDIT) excl Other Income
-2.70
0.20
-1,450.00%
Interest
0.00
0.10
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-2.70
-2.20
-22.73%
Operating Profit Margin (Excl OI)
-287.20%
-222.30%
-6.49%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is -2.08% vs -5.88% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -22.73% vs -100.00% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
38.80
35.20
10.23%
Operating Profit (PBDIT) excl Other Income
-7.30
-4.50
-62.22%
Interest
0.00
0.60
-100.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-7.70
-10.90
29.36%
Operating Profit Margin (Excl OI)
-188.10%
-296.90%
10.88%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 10.23% vs 17.33% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 29.36% vs 64.14% in Dec 2024
About Glycorex Transplantation AB 
Glycorex Transplantation AB
Pharmaceuticals & Biotechnology
Glycorex Transplantation publ AB is a Sweden-based medical device company engaged in the research, development, production and sales of medical devices within the field of organ transplantation. The Company's main product, Glycosorb-ABO, facilitates organ transplantation between different blood types. Additionally, the Company has developed complementary product variants, such as Glycosorb-ABO A/B-kolonn, designed for different patient categories, and Glycosorb-Xeno, which can facilitate transplants between animals and humans. As of December 31, 2011, Glycosorb-ABO was used in 103 transplantation centers in 22 countries. As of December 31, 2011, the Company had four wholly owned subsidiaries, namely Glycoprobe AB, Glycorex Transplantation, Glycorex UMC AB and Glycorex UBP AB.
Company Coordinates 
Company Details
Scheelevagen 27 , LUND None : 223 63
Registrar Details






